BGMS

SEC Filing Summary: Xcyte Therapies, Inc. (10-Q)

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2004, for Xcyte Therapies, Inc. (Note: The input metadata referenced "Bio Green Med Solution, Inc.", but the filing text explicitly identifies the registrant as Xcyte Therapies, Inc.). Xcyte is a development-stage biotechnology company focused on creating therapeutic products based on T-cell activation (Xcellerate Technology) to treat cancer, infectious diseases, and immune-compromised conditions. The company has no commercial product sales and relies on capital raises, grants, and collaboration agreements for funding.

Key Financial Metrics

Note: Revenue consists of license fees, collaborative agreement reimbursements, and government grants. The company reported no product sales.

Material Changes vs. Prior Period

• Revenue Decline: Revenue for the three months ended September 30, 2004, dropped to $13,000 from $73,000 in the same period in 2003. For the nine-month period, revenue was $49,000 compared to $145,000 in 2003.
• Expense Increases:
  • R&D Expenses: Increased 66% year-over-year for the quarter (from $3.1M to $5.1M) and 36% for the nine-month period (from $10.1M to $13.7M). Drivers included higher clinical trial costs, laboratory supplies, and personnel expansion (R&D staff grew from 50 to 83).
  • G&A Expenses: Increased 91% for the quarter (from $0.9M to $1.8M) and 62% for the nine-month period (from $3.1M to $5.0M), driven by professional fees, insurance, and stock compensation.
• Significant Non-Cash Interest Expense: Interest expense for the nine months ended September 30, 2004, spiked to $12.7 million (compared to $0.2 million in 2003). This was primarily due to the recognition of $11.3 million in interest expense related to the beneficial conversion feature of convertible promissory notes upon the company's Initial Public Offering (IPO) in March 2004.
• Preferred Stock Accretion: The company recognized $9.0 million in accretion of preferred stock during the nine-month period, associated with the conversion of Series E and F preferred stock into common stock during the IPO.
• Liquidity Improvement: Cash and short-term investments increased significantly from $13.5 million at December 31, 2003, to $27.2 million at September 30, 2004, following the March 2004 IPO which raised net proceeds of approximately $29.7 million.

Guidance, Outlook, and Risks

• Capital Resources: Management believes current cash, cash equivalents, and investments ($27.2 million as of Sept 30, 2004) plus proceeds from a November 2004 preferred stock offering ($27.5 million) will fund operations through at least the end of the second quarter of 2006. Additional financing will likely be required before that date for Phase II/III trials.
• Subsequent Event: On November 3, 2004, the company completed a public offering of 2,990,000 shares of 6% convertible exchangeable preferred stock at $10.00 per share, raising net proceeds of $27.5 million.
• Clinical Development: The company plans to submit a Phase II/III clinical trial protocol for Chronic Lymphocytic Leukemia (CLL) to the FDA in the fourth quarter of 2004, with a goal to initiate the pivotal trial by the end of the second quarter of 2005. Success is contingent on FDA acceptance of the protocol.
• Key Risks:
  • Regulatory Uncertainty: The FDA may not accept the proposed clinical trial protocol or may require additional studies, delaying commercialization.
  • Manufacturing: The company relies on a single manufacturing facility and a custom bioreactor system. Scaling up production for commercial use poses significant technical and regulatory challenges.
  • Supplier Dependence: Critical components (antibodies, magnetic beads, bioreactors) are sourced from single suppliers (Lonza, Dynal, Wave Biotech). Disruption in these supply chains could halt clinical trials.
  • Profitability: The company has incurred significant losses since inception ($117.8 million accumulated deficit) and expects to continue incurring losses for several years.

Investor Verification Checklist

• Verify the status of the FDA review for the Phase II/III CLL clinical trial protocol expected in Q4 2004.
• Confirm the terms and conversion mechanics of the November 2004 convertible preferred stock offering.
• Assess the stability of supply agreements with Lonza (antibodies), Dynal (beads), and Wave Biotech (bioreactors), noting the single-source dependency.
• Monitor cash burn rate against the projected runway to Q2 2006 to determine the timing of future capital raises.
• Review the impact of the $12.7 million non-cash interest expense on the company's reported net loss versus its actual cash operating burn.